Antonio M Risitano Selected Research

L-Lactate Dehydrogenase (Lactate Dehydrogenase)

5/2021	Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
7/2013	Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.
2/2008	Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
9/2006	The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antonio M Risitano Research Topics

Disease

39	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 03/2024 - 05/2002
26	Hemolysis 01/2023 - 09/2006
21	Aplastic Anemia (Anemia, Hypoplastic) 12/2023 - 05/2002
10	Anemia 03/2024 - 02/2008
8	Fatigue 03/2024 - 09/2006
6	Hemolytic Anemia 03/2024 - 06/2008
6	COVID-19 08/2022 - 01/2020
4	Bone Marrow Failure Disorders 05/2021 - 01/2013
4	Hematologic Diseases (Blood Diseases) 01/2018 - 06/2008
3	Neoplasms (Cancer) 03/2024 - 09/2006
3	Chronic Disease (Chronic Diseases) 09/2022 - 09/2006
3	idiopathic Aplastic anemia 01/2022 - 01/2019
3	Infections 01/2021 - 11/2015
3	Cytopenia 01/2019 - 04/2002
3	Large Granular Lymphocytic Leukemia 01/2007 - 02/2004
2	Inflammation (Inflammations) 11/2020 - 12/2015
2	Thrombotic Microangiopathies 11/2020 - 01/2016
2	Disease Progression 01/2020 - 01/2016
2	Thrombocytopenia (Thrombopenia) 01/2019 - 02/2008
2	Atypical Hemolytic Uremic Syndrome 01/2016 - 06/2015
2	Thrombophilia 12/2014 - 01/2013
2	Hemoglobinuria 01/2013 - 06/2008
2	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2012 - 03/2011
2	Leukemia 06/2004 - 11/2002
1	Immune System Diseases (Immune Disorders) 01/2023
1	Injection Site Reaction 09/2022
1	Nasopharyngitis 09/2022
1	Philadelphia Chromosome 07/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 07/2021
1	Diamond-Blackfan Anemia (Anemia, Diamond Blackfan) 01/2021
1	Communicable Diseases (Infectious Diseases) 01/2021
1	Tuberculosis (Tuberculoses) 01/2021
1	Thromboinflammation 11/2020
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 11/2020
1	Lung Injury 01/2020
1	Cytokine Release Syndrome 01/2020
1	Pneumonia (Pneumonitis) 01/2020
1	Pure Red-Cell Aplasia 11/2019
1	Arthritis (Polyarthritis) 01/2019
1	Sickle Cell Anemia (Hemoglobin S Disease) 01/2019
1	Neutropenia 01/2019
1	Membranous Glomerulonephritis (Membranous Nephropathy) 01/2019
1	Malaria 10/2016
1	Fanconi Anemia (Fanconi's Anemia) 03/2016

Drug/Important Bio-Agent (IBA)

32	Complement System Proteins (Complement)IBA 09/2023 - 09/2006
28	eculizumab FDA Link 09/2022 - 09/2006
7	Monoclonal AntibodiesIBA 11/2020 - 09/2006
5	Complement Inactivating AgentsIBA 03/2024 - 09/2006
5	Hemoglobins (Hemoglobin)IBA 03/2024 - 07/2008
5	compstatinIBA 08/2022 - 03/2014
5	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021 - 05/2002
5	Proteins (Proteins, Gene)FDA Link 01/2013 - 04/2002
4	eltrombopag FDA Link 12/2023 - 01/2019
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 05/2021 - 09/2006
4	AntigensIBA 01/2021 - 07/2002
3	AMY-101IBA 08/2022 - 01/2020
3	Complement C3 (C3 Complement)IBA 08/2022 - 01/2020
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022 - 06/2011
3	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2022 - 08/2010
3	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 11/2021 - 10/2011
3	CytokinesIBA 11/2020 - 02/2004
3	Complement Factor H (Factor H)IBA 01/2019 - 06/2012
2	pegcetacoplanIBA 09/2022 - 01/2022
2	danicopanIBA 12/2021 - 11/2021
2	Tyrosine Kinase InhibitorsIBA 07/2021 - 02/2014
2	Complement Factor B (Factor B)IBA 05/2021 - 01/2019
2	Interleukin-6 (Interleukin 6)IBA 11/2020 - 01/2020
2	Alemtuzumab (Campath)FDA Link 10/2018 - 01/2012
2	anticomplementIBA 01/2018 - 01/2013
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2015 - 01/2012
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2014 - 11/2012
2	Complement 3d Receptors (Complement Receptor 2)IBA 01/2013 - 06/2012
2	HLA Antigens (Human Leukocyte Antigens)IBA 08/2012 - 05/2002
2	thymoglobulin FDA Link 06/2012 - 01/2012
2	Prion ProteinsIBA 01/2003 - 07/2002
1	BilirubinIBA 03/2024
1	Bispecific AntibodiesIBA 03/2024
1	Complement Factor D (Factor D)IBA 12/2021
1	Alanine Transaminase (SGPT)IBA 12/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2021
1	ponatinibIBA 07/2021
1	SteroidsIBA 05/2021
1	Biomarkers (Surrogate Marker)IBA 05/2021
1	ravulizumabIBA 01/2021
1	C-Reactive ProteinIBA 11/2020
1	Thrombopoietin ReceptorsIBA 06/2019
1	Hemin (Panhematin)FDA Link 10/2016
1	AntibodiesIBA 03/2016
1	Dihydrotachysterol (AT 10)IBA 03/2016

Therapy/Procedure

14	Therapeutics 03/2024 - 09/2006
8	Hematopoietic Stem Cell Transplantation 01/2022 - 06/2010
5	Transplantation 01/2022 - 08/2010
5	Stem Cell Transplantation 01/2021 - 01/2011
2	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2022 - 01/2005
2	Homologous Transplantation 07/2021 - 10/2012
1	Treatment Delay 01/2022
1	Blood Transfusion (Blood Transfusions) 11/2021
1	Traction 11/2020
1	Oral Administration 01/2019
1	Erythrocyte Transfusion 01/2019